Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting
April 20, 2016 10:46 ET
|
Genmab A/S
Company Announcement
Oral plenary session presentation on daratumumab Phase III Castor study data
Trial in progress poster presentation from Phase I study of subcutaneous...
Genmab Updates Financial Guidance for 2016
April 20, 2016 01:03 ET
|
Genmab A/S
Company Announcement
Genmab improves financial guidance for 2016
Improvement driven by DARZALEX® sales
Rapid uptake of the product since launch
Copenhagen, Denmark; April 20, 2016 –...
Genmab opjusterer resultatforventningerne til 2016
April 20, 2016 01:03 ET
|
Genmab A/S
Selskabsmeddelelse
Genmab opjusterer resultatforventningerne til 2016
Opjusteringen er drevet af salget af DARZALEX®
Hurtigt optag af produktet siden lancering
København, Danmark;...
Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX®
April 04, 2016 14:00 ET
|
Genmab A/S
Company Announcement
Morphosys AG files patent infringement complaint against Genmab and Janssen Biotech, Inc. with the US District Court of Delaware
Complaint is under US patent no....
Retssag om patentkrænkelse anlagt mod Genmab og Janssen i USA vedrørende DARZALEX®
April 04, 2016 14:00 ET
|
Genmab A/S
Selskabsmeddelelse
Morphosys AG har anlagt retssag med påstand om patentkrænkelse mod Genmab og Janssen Biotech, Inc. ved den amerikanske distriktsdomstol i Delaware
Retssagen vedrører US...
CHMP afgiver positiv udtalelse og anbefaler DARZALEX® (daratumumab) i recidiverende og refraktær myelomatose
April 01, 2016 11:34 ET
|
Genmab A/S
Selskabsmeddelelse
CHMP afgiver positiv udtalelse for DARZALEX til behandling af recidiverende og refraktær myelomatose
Den endelige afgørelse fra Europa-Kommissionen ventes i de kommende...
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed and Refractory Multiple Myeloma
April 01, 2016 11:34 ET
|
Genmab A/S
Company Announcement
CHMP issued positive opinion for DARZALEX for relapsed and refractory multiple myeloma
Final decision from European Commission expected in the coming...
Genmab offentliggør positivt interimresultat fra fase III studiet Castor med daratumumab til behandling af recidiverende eller refraktær myelomatose
March 30, 2016 12:13 ET
|
Genmab A/S
Selskabsmeddelelse
Fase III studiet Castor med daratumumab i kombination med bortezomib og dexamethason til behandling af recidiverende eller refraktær myelomatose opfyldte det primære endpoint...
Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
March 30, 2016 12:13 ET
|
Genmab A/S
Company Announcement
Phase III Castor study of daratumumab in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma met primary endpoint at pre-planned...
Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma
March 21, 2016 13:12 ET
|
Genmab A/S
Company Announcement
Phase Ib studies of daratumumab in combination with Roche’s immune checkpoint inhibitor atezolizumab in a solid tumor and multiple myeloma to be started
Studies...